The Breast Cancer Research Program includes 29 faculty members from eight departments and two schools to form an integrated program that is dedicated to research on the prevention, diagnosis and treatment of breast cancer. The program is currently supported by $3,465,104 in NCI funding and $4,755,188 in other peer-reviewed funding. Program members have diverse interests including research into breast health communications, the pathology and biology of premalignant lesions, the development of intrinsic breast cancer subtype assays, translational research on endocrine therapy resistance in the context of cooperative group neoadjuvant endocrine therapy trials, the development of novel therapeutics that target both tumor cells and bone and the immune system cells. We are also very actively investigating novel imaging approaches for predicting response to hormonal therapy. In addition, the program is now collaborating with the Washington University Genome Sequencing Center in an effort to unravel the genetic changes associated with breast susceptibility, initiation, progression, relapse, and resistance. Program members are developing new breast cancer models in order to develop preclinical justifications for investigator initiated clinical trials in our developmental therapeutics programs. Classes of agent under development include phosphoinositol-3-kinase inhibitors, hedgehog inhibitors, check point homolog kinase (CHK1) inhibitors and Trop2 antibodies. The program consists of a number of basic, translational, and clinical investigators who meet weekly in a highly interactive scientific milieu. Large numbers of breast cancer patients are being treated on clinical protocols at Washington University with a number of Siteman Cancer Center cores are essential for the mission ofthe program, including the Clinical Trials Core, Imaging Response Assessment Team, Tissue Procurement Core, the Molecular and Genomic Analysis Core, the Biostatistics Core, the Bioinformatics Core, and the Proteomics Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA091842-13
Application #
8705877
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Kuroki, Lindsay M; Frolova, Antonina I; Wu, Ningying et al. (2017) Yield of Cytology Surveillance After High-Grade Vulvar Intraepithelial Neoplasia or Cancer. J Low Genit Tract Dis 21:193-197
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Eberth, Jan M; Josey, Michele J; Mobley, Lee R et al. (2017) Who Performs Colonoscopy? Workforce Trends Over Space and Time. J Rural Health :
Wang, Xuya; Mooradian, Arshag D; Erdmann-Gilmore, Petra et al. (2017) Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Sci Signal 10:
Knoop, Kathryn A; Gustafsson, Jenny K; McDonald, Keely G et al. (2017) Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. Sci Immunol 2:
Cusworth, Brian M; Krasnick, Bradley A; Nywening, Timothy M et al. (2017) Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 19:147-153
Song, Hao; Ruan, Dan; Liu, Wenyang et al. (2017) Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. Med Phys 44:962-973
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105
Ee, Xueping; Yan, Ying; Hunter, Daniel A et al. (2017) Transgenic SCs expressing GDNF-IRES-DsRed impair nerve regeneration within acellular nerve allografts. Biotechnol Bioeng 114:2121-2130

Showing the most recent 10 out of 1109 publications